DSIP Peptide Dosage: A Patient Guide to Delta Sleep-Inducing Peptide

DSIP (Delta Sleep-Inducing Peptide), known in compounding as emideltide, has been investigated in study-specific dosing such as 25 nmol/kg and is often discussed in educational materials around 100–300 mcg near bedtime. DSIP is not FDA-approved, has no official dosing guideline, and any use requires a licensed clinician’s evaluation [1,2,3].

What is DSIP (Delta Sleep-Inducing Peptide)?

DSIP (Delta Sleep-Inducing Peptide) is a small chain of 9 amino acids, also called a nonapeptide neuropeptide. It was first studied because of possible effects on sleep patterns, including slow-wave delta sleep, but it is not FDA-approved for insomnia, sleep quality, recovery, anxiety, or any other medical use [1,2].

In compounding, DSIP may be referred to as emideltide, a compounding name for the same peptide class. Compounded DSIP via a licensed 503A pharmacy is different from an FDA-approved drug: 503A pharmacies compound patient-specific prescriptions, but compounded products are not FDA-approved for safety or effectiveness [1,6].

Emideltide: the compounding name

Emideltide is the name used by some compounding sources for DSIP. The name does not mean the product has an FDA-approved indication, FDA-reviewed dose, approved route, or approved drug label [1,3].

How DSIP is thought to work

DSIP has been investigated for sleep regulation, pain signaling, stress biology, and endocrine pathways, including the HPA axis, which links the brain, pituitary gland, adrenal glands, and cortisol release [2,4,7]. Some research also discusses possible links with GABA neurotransmission, but the mechanism is not settled and modern clinical evidence is limited [4,7].

Because DSIP is still investigational for sleep, possible benefits should be viewed alongside safety gaps. Reported and theoretical concerns include next-day sedation, dizziness, headache, mood changes, interaction risk with sedatives, and unknown long-term effects [4,8,9].

What dose of DSIP is used in research?

DSIP has no FDA-approved dose. Published and educational sources describe study-specific protocols, including a historical insomnia study in which researchers administered 25 nmol/kg DSIP, and some compounding education materials discuss 100–300 mcg ranges; these are not instructions for personal use [2,3].

The 100–300 mcg range

Some peptide-clinic educational materials describe DSIP ranges around 100–300 mcg given near bedtime, but these are not FDA-label doses and are not backed by a modern FDA-approved DSIP prescribing label [1,3]. Because DSIP remains non-approved, these figures should be treated as background information for a clinician discussion, not as a protocol.

Historical protocols: 25 nmol/kg studies

In a small human insomnia study indexed in PubMed, researchers administered DSIP at 25 nmol/kg and evaluated sleep in a controlled research setting; the same study context means results may not apply to routine home use, and individual results vary [2]. Safety interpretation is limited by older methods, small study size, and lack of long-term follow-up [2,4].

Why there is no FDA-approved dose

An FDA-approved dose usually comes from a reviewed drug application with evidence for quality, safety, effectiveness, labeling, contraindications, and manufacturing controls [1]. DSIP does not have that kind of FDA-approved drug label, so there is no FDA-recognized dose, titration plan, half-life guidance, or patient leaflet [1,6].

How is DSIP administered?

DSIP is most often discussed as a subcutaneous injection, meaning an injection under the skin, but some sources also describe nasal or sublingual forms. No DSIP route is FDA-approved, and route choice affects absorption, sterility risk, and side effects [1,3,6].

Subcutaneous injection

Subcutaneous injection is the route most often used for compounded peptides because it can deliver a measured amount under the skin. For DSIP, that does not make the treatment FDA-approved, and injection can add risks such as pain, redness, infection, dosing error, and accidental contamination [1,5,6].

Nasal and sublingual forms

Nasal sprays and sublingual drops are sometimes discussed for peptides, but DSIP does not have an FDA-approved nasal or sublingual label. Absorption can vary more with these routes, and quality controls depend on whether the product is prepared by a licensed pharmacy under a valid prescription [1,6].

Injection sites and technique

Patients should not learn injection technique from social media or unlabeled vials. If a clinician prescribes a compounded injectable peptide, the pharmacy and care team should provide product-specific directions for site rotation, sterile handling, sharps disposal, missed doses, and when to call for help [5,6].

When should DSIP be taken?

DSIP timing is not standardized because there is no FDA-approved label. Some educational protocols discuss evening use about 30–60 minutes before bedtime, but this is not an official recommendation and may be unsafe with alcohol, benzodiazepines, Z-drugs, opioids, or other sedating medicines [3,8,9,10].

Evening timing 30–60 minutes before bed

The reason evening timing is discussed is simple: DSIP is being considered for sleep, so researchers and clinics often place it near the sleep window. That timing may also raise safety concerns, including next-day grogginess, impaired driving, falls, or additive sedation when combined with other sleep medicines [8,9,10].

Daily vs cycled use

There is no FDA-approved daily or cycled DSIP schedule. Claims about cycling are usually based on clinic practice or theory, not large randomized trials, and long-term safety data are not strong enough to assume that repeated use is low risk [1,4].

How is a DSIP vial reconstituted?

Reconstitution means adding sterile liquid to a dry peptide powder, often bacteriostatic water when a pharmacy instructs it. A concentration-only math example is a 10 mg vial with 3 mL of diluent, but this is arithmetic education only, not a DSIP prescription or handling instruction [5,6].

Example: 10 mg vial with 3 mL bacteriostatic water

In a concentration-only example, 10 mg mixed with 3 mL equals 3.33 mg/mL. This math does not say how much DSIP to inject, whether the vial is sterile, whether bacteriostatic water is appropriate, or whether DSIP is safe for a specific person [5,6].

Reading units on an insulin syringe

Insulin syringes can be confusing because “units” measure volume, not peptide mass. A dosing error can happen if someone confuses micrograms, milligrams, milliliters, or syringe units, which is why a pharmacist or clinician should teach any prescribed injectable medicine [5,6].

Storage and stability

Storage depends on the exact formulation, diluent, sterility process, beyond-use date, and pharmacy label. If DSIP is prescribed, follow the pharmacy’s storage instructions and discard rules; do not rely on generic internet claims about how long a reconstituted peptide lasts [5,6].

What are the side effects and safety concerns?

DSIP side effects are not well mapped because modern human trials are limited. Reported or plausible concerns include sleepiness, vivid dreams, headache, dizziness, nausea, mood changes, injection-site irritation, and unknown effects with longer-term use [2,4].

Reported tolerability

Older DSIP studies and reviews describe mixed findings, and they do not provide the same safety confidence as large modern trials [2,4]. Any possible sleep-related benefit must be balanced against limited data, especially for people using alcohol, sedatives, antidepressants, opioids, or other medicines that affect the brain [8,9,10].

Limits of long-term safety data

Long-term DSIP safety is uncertain. There is not enough high-quality evidence to know how repeated use may affect hormones, cortisol rhythm, mood, pregnancy, seizure risk, breathing during sleep, or next-day alertness [1,4].

Who should avoid DSIP

People who are pregnant, trying to become pregnant, breastfeeding, younger than 18, using sedatives, living with untreated sleep apnea, or managing major psychiatric, neurologic, liver, kidney, or endocrine conditions should not use DSIP without a careful medical review. This caution is important because DSIP is not FDA-approved and does not have formal contraindication labeling [1,4,8].

How does DSIP compare with other sleep options?

DSIP is investigational, while melatonin, benzodiazepines, and Z-drugs have clearer regulatory histories. That does not make any sleep option risk-free; each has different evidence, side effects, interactions, and safety concerns [8,9,10,11].

DSIP vs melatonin

Melatonin is a hormone sold as a supplement in the United States, while DSIP is an investigational peptide. Melatonin has more consumer use and public safety guidance, but it can still cause side effects and interact with medicines; DSIP has less modern safety evidence [11].

DSIP vs benzodiazepines and Z-drugs

Benzodiazepines and Z-drugs may support sleep in selected patients when used under labeled conditions, but they have well-known risks, including dependence, falls, next-day impairment, respiratory depression, and complex sleep behaviors [8,9,10]. DSIP is not known to carry the same labeled risks because it has no FDA label, but that also means its risks are less clearly defined [1,4].

DSIP vs epitalon

Epitalon is another investigational peptide sometimes discussed in sleep and longevity settings, but it is not FDA-approved for those uses. Compared with DSIP, epitalon is more often discussed for circadian or aging biology; both have limited U.S. clinical data and need clinician oversight [12].

How can you get DSIP legally in the United States?

DSIP is not an FDA-approved drug, so legal access is different from filling a standard FDA-approved sleep medication. A patient-specific compounded DSIP prescription may be considered only when allowed under federal and state compounding rules, and it should come through a licensed clinician and pharmacy, not a research-chemical website [1,5,6].

FDA Category 2 removal in April 2026

FDA’s 503A bulk drug substance process affects whether certain substances may be used in traditional pharmacy compounding. DSIP was addressed in FDA’s April 15–16, 2026 reclassification materials and is currently under FDA review, so FDA.gov should be checked directly because the status can change [3,6].

The July 2026 advisory review

DSIP is currently under FDA review, with the Pharmacy Compounding Advisory Committee scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026 [3]. This is not FDA approval, and it does not mean DSIP is proven safe or effective for sleep [1,3].

Why “research use only” vendors are risky

Peptides sold online as “research use only” are not intended for human treatment. They may lack patient-specific labeling, sterility assurance, potency testing, adverse-event support, and legal safeguards that come with a licensed prescriber and pharmacy [5,6].

Getting a clinician-reviewed prescription through Chia

If you are exploring compounded longevity peptides, Chia is one telehealth option that can connect eligible patients with a clinician review and licensed 503A pharmacy partners when a prescription is appropriate. Other licensed sleep specialists, primary care clinicians, and telehealth providers may also be appropriate paths, especially if symptoms suggest sleep apnea, depression, restless legs, or medication side effects [6,13].

What peptides stack well with DSIP?

DSIP stacks are not FDA-approved protocols. In clinical and research practice, DSIP may be discussed alongside peptides such as epitalon, BPC-157, or semax, but combination-specific trials are limited and no combined dosing schedule is established [1,4,12].

• DSIP + epitalon: This pairing is discussed in longevity and circadian-rhythm contexts because DSIP is studied for sleep architecture and epitalon has been investigated in aging-related neuroendocrine research. The safety caveat is that both are non-FDA-approved for sleep or longevity, and combined effects on hormones, mood, and next-day alertness are not well studied [4,12].
• DSIP + BPC-157: This combination is sometimes discussed in recovery-focused peptide practice because DSIP is sleep-oriented and BPC-157 is studied in tissue-repair models. The safety caveat is that BPC-157 is not FDA-approved for recovery or tissue repair, and there are no strong human trials proving that adding it to DSIP improves outcomes [14].
• DSIP + semax: This pairing is sometimes discussed in neuropeptide practice because semax has been studied for central nervous system signaling while DSIP is studied for sleep-related pathways. The safety caveat is that combining a sleep-focused peptide with a neuroactive peptide may affect mood, alertness, blood pressure, or sleep quality in unpredictable ways [4,15].

Frequently asked questions about DSIP dosing

Keep reading

Longevity Peptides

DSIP Peptide: What It Is, How It Works, and What the Evidence Shows

Longevity Peptides

MOTS-c Peptide: What It Is, How It Works, and How to Get It

Peptides

The Wolverine Peptide Stack: BPC-157 + TB-500 Evidence, Risks, and FDA Status